{"Clinical Trial ID": "NCT00375505", "Intervention": ["INTERVENTION 1:", "- Placebo", "\u2022 Placebo infusion of 15 minutes every 3 months for a 24 month treatment period (total of 8 infusions).", "INTERVENTION 2:", "- Zometa", "zoledronic acid 4mg as a 15-minute infusion every 3 months for a 24-month treatment period (total of 8 infusions)."], "Eligibility": ["Incorporation criteria:", "In women with invasive breast cancer (T1-4) confirmed by histology and with positive hormonal receptor status (ER and/or PgR positive) and no evidence of regional metastases of lymph nodes (N0) or distant metastases (M0)", "The patient underwent complete primary tumour resection and dissection of the axillary lymph nodes less than 90 days prior to the start of the study drug treatment.", "The patient is premenopausal at the time of diagnosis of breast cancer (spontaneous pathways and regular rules with premenopausal estradiol levels (>10 ng/dL)", "The patient receives a standard adjuvant chemoendocrine or endocrine treatment.", "At baseline bone density > -2.5 T-Score", "- Exclusion criteria:", "\u2022 History of treatment or disease affecting bone metabolism (e.g. Paget disease, primary hyperparathyroidism), prior treatment with bisphosphonates or treatment of osteoporosis in addition to calcium and vitamin D", "Abnormal renal function", "Current active dental problems, including tooth or jaw infection (maxilla or mandible); dental or fixture trauma, or a current or previous diagnosis of osteonecrosis of the jaw (ONJ), bone exposed in the mouth, or slow healing after recent dental intervention (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants)", "Pregnancy or lactation", "- Women of childbearing potential who do not use medically recognized contraception (i.e., contraceptives or oral implants, IDU, vaginal or sponge diaphragm, or spermicide condom)", "Other inclusion/exclusion criteria defined by the Protocol may apply."], "Results": ["Performance measures:", "Change in bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) to the lumbar spine (L2-L4) From reference to month 24", "Two X-ray beams with different energy levels are intended for the patient's bones. When the absorption of soft tissue is subtracted, the BMD can be determined from the absorption of each beam by the bone.", "Timeline: base of reference, months 24", "Results 1:", "Title of the arm/group: Placebo", "Description of the arm/group: Placebo infusion of 15 minutes every 3 months for a 24-month treatment period (total of 8 infusions).", "Total number of participants analysed: 36", "Average (standard deviation)", "Unit of measurement: Z-score -0.075 (0.041)", "Results 2:", "Title of the arm/group: Zometa", "Description of the arm/group: Zoledronic acid 4mg as a 15-minute infusion every 3 months for a 24-month treatment period (total of 8 infusions).", "Total number of participants analysed: 34", "Average (standard deviation)", "Unit of measurement: Z-score 0.037 (0.042)"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/36 (8.33 per cent)", "VERTIGO 0/36 (0.00 %)", "DENTAL CARIES 1/36 (2.78 %)", "GASTROINTESTINAL OEDEMA 1/36 (2.78 %)", "HEMATOCHEZIE 0/36 (0.00 %)", "PANCREATITIS 1/36 (2.78 %)", "PYREXIA 1/36 (2.78 %)", "- DRUG HYPERSENSITIVITY 0/36 (0.00 %)", "FEBRUARY INFECTION 0/36 (0.00 %)", "SUBCUTANES 1/36 (2.78 per cent)", "OST\u00c9ONECROSE 0/36 (0.00 %)", "CANCER BREAST 1/36 (2.78%)", "OSTEOMA 1/36 (2.78 %)", "Adverse Events 2:", "Total: 6/34 (17.65%)", "VERTIGO 1/34 (2.94 %)", "- DENTAL CARIES 0/34 (0.00 %)", "GASTROINTESTINAL OEDEMA 0/34 (0.00 %)", "HEMATOCHEZY 1/34 (2.94%)", "PANCREATITIS 0/34 (0.00 %)", "PYREXIA 0/34 (0.00 %)", "HYPERSENSITIVENESS OF DRUGS 1/34 (2.94 %)", "FEBRUARY INFECTION 1/34 (2.94%)", "SUB-CUTAGNE ABSCES 0/34 (0.00 %)", "OST\u00c9ONECROSE 1/34 (2.94%)", "CANCER BREAST 1/34 (2.94 %)", "OSTEOMA 0/34 (0.00 %)"]}